AMRX - Amneal Pharmaceuticals Inc Stock Price, Fair Value and News

7.43USD+0.05 (+0.68%)Market Closed

Market Summary

USD7.43+0.05

Market Closed

0.68%

AMRX Stock Price

View Fullscreen

AMRX RSI Chart

AMRX Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-14.37

Price/Sales (Trailing)

0.92

EV/EBITDA

42.08

Price/Free Cashflow

14.45

AMRX Price/Sales (Trailing)

AMRX Profitability

EBT Margin

-4.26%

Return on Equity

250.86%

Return on Assets

-4.62%

Free Cashflow Yield

6.92%

AMRX Fundamentals

AMRX Revenue

Revenue (TTM)

2.5B

Rev. Growth (Yr)

18.23%

Rev. Growth (Qtr)

6.84%

AMRX Earnings

Earnings (TTM)

-159.6M

Earnings Growth (Yr)

-1.2K%

Earnings Growth (Qtr)

13.34%

Breaking Down AMRX Revenue

Last 7 days

2.6%

Last 30 days

14.8%

Last 90 days

26.6%

Trailing 12 Months

145.2%

How does AMRX drawdown profile look like?

AMRX Financial Health

Current Ratio

1.65

Debt/Equity

-37.37

Debt/Cashflow

0.08

AMRX Investor Care

Shares Dilution (1Y)

102.91%

Diluted EPS (TTM)

-0.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.5B	0	0	0
2023	2.3B	2.3B	2.4B	2.4B
2022	2.1B	2.1B	2.1B	2.2B
2021	2.0B	2.1B	2.1B	2.1B
2020	1.7B	1.7B	1.9B	2.0B
2019	1.8B	1.8B	1.7B	1.6B
2018	1.1B	1.2B	1.5B	1.7B
2017	1.0B	1.0B	1.0B	1.0B
2016	0	0	0	1.0B

Get all data in R, Python etc through our Historical Stock Data APIs

About Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

CEO	Mr. Chirag K. Patel
WEBSITE	https://amneal.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	7600

Amneal Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Amneal Pharmaceuticals Inc? What does AMRX stand for in stocks?

AMRX is the stock ticker symbol of Amneal Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amneal Pharmaceuticals Inc (AMRX)?

As of Fri Jul 26 2024, market cap of Amneal Pharmaceuticals Inc is 2.29 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMRX stock?

You can check AMRX's fair value in chart for subscribers.

Is Amneal Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMRX is over valued or under valued. Whether Amneal Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Amneal Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMRX.

What is Amneal Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, AMRX's PE ratio (Price to Earnings) is -14.37 and Price to Sales (PS) ratio is 0.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMRX PE ratio will change depending on the future growth rate expectations of investors.